XmAb-13677

N/A

Report date: 2026/03/19 16:59:48

Base Information

Drug NameXmAb-13677

Drug Alias NameXmAb-13677

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD20Anti-CD3

TargetsT cell surface glycoprotein CD3B-lymphocyte antigen CD20

Therapy Area/IndicationsLeukemia, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesXencor Inc

China Registration ClassN/A

Develop Information

Active CompaniesXencor Inc

Inactive CompaniesN/A

Active IndicationsLeukemia, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A